Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results

被引：7

作者：

Chi, Kim N. ^{[1
]}

Fleshner, Neil ^{[2
]}

Chiuri, Vincenzo Emanuele ^{[3
]}

Van Bruwaene, Siska ^{[4
]}

Hafron, Jason ^{[5
]}

McNeel, Douglas G. ^{[6
]}

De Porre, Peter ^{[7
]}

Maul, Raymond Scott ^{[8
]}

Daksh, Mahesh ^{[9
]}

Zhong, Xiaogang ^{[10
]}

Mason, Gary E. ^{[11
]}

Tutrone, Ronald F. ^{[12
]}

机构：

[1] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada

[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] I Veris Delli Ponti Hosp, Lecce, Italy

[4] AZ Groeninge Hosp, Dept Urol, Kortrijk, Belgium

[5] Michigan Inst Urol, W Bloomfield, MI USA

[6] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[7] Janssen Res & Dev, Beerse, Belgium

[8] Janssen Res & Dev, Los Angeles, CA USA

[9] Janssen Res & Dev, Raritan, NJ USA

[10] Janssen Res & Dev, College Pk, MD USA

[11] Janssen Res & Dev, Spring House, PA USA

[12] Chesapeake Urol Res Assoc, Towson, MD USA

来源：

ONCOLOGIST | 2023年 / 28卷 / 05期

关键词：

castration-resistant prostate cancer; PARP inhibitor; homologous recombination repair; niraparib; abiraterone acetate;

D O I：

10.1093/oncolo/oyad008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.

引用

页码：E309 / E312

页数：4

共 50 条

[1] NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE PHASE 2 QUEST STUDY
Chi, Kim
Fleshner, Neil
Chiuri, Vincenzo Emanuele
Van Bruwaene, Siska
Hafron, Jason
McNeel, Douglas G.
De Porre, Peter
Maul, R. Scott
Daksh, Mahesh
Zhong, Xiaogang
Mason, Gary E.
Tutrone, Ronald
JOURNAL OF UROLOGY, 2022, 207 (05): : E456 - E457
[2] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Chi, Kim N.
Rathkopf, Dana
Smith, Matthew R.
Efstathiou, Eleni
Attard, Gerhardt
Olmos, David
Lee, Ji Youl
Small, Eric J.
Gomes, Andrea J. Pereira De Santana
Roubaud, Guilhem
Saad, Marniza
Zurawski, Bogdan
Sakalo, Valerii
Mason, Gary E.
Francis, Peter
Ms, George Wang
Wu, Daphne
Diorio, Brooke
Lopez-Gitlitz, Angela
Sandhu, Shahneen
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
[3] COST-EFFECTIVENESS OF NIRAPARIB PLUS ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Duru, E.
Mattingly, T. J.
Malone, D. C.
VALUE IN HEALTH, 2024, 27 (06) : S62 - S62
[4] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Auchus, Richard J.
Yu, Margaret K.
Nguyen, Suzanne
Mundle, Suneel D.
ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
[5] Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone
Duarte, C.
Jimeno, A.
Kessler, E. R.
DRUGS OF TODAY, 2019, 55 (01) : 5 - 15
[6] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
Yang, Lily P. H.
DRUGS, 2011, 71 (15) : 2067 - 2077
[7] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Einstein, David Johnson
Choudhury, Atish Dipankar
Saylor, Philip James
Werner, Lillian
Erlander, Mark G.
Ridinger, Maya
Bubley, Glenn
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[8] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Einstein, David Johnson
Choudhury, Atish Dipankar
Saylor, Philip James
Patterson, Jesse Christopher
Croucher, Peter
Ridinger, Maya
Erlander, Mark G.
Yaffe, Michael B.
Bubley, Glenn
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[9] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
L. P. H. Yang
Drugs, 2012, 72 (2) : 192 - 192
[10] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64

← 1 2 3 4 5 →